P2RY12 and coronary artery disorder: The ENTRUST-AF PCI trial, an open-label, randomised, multicentre trial compared triple therapy consisting of VKA, P2Y12 inhibitor (mainly clopidogrel) and ASA (for 1–12 months guided by clinical presentation with either stable coronary artery disease or ACS) to the factor Xa-antagonist edoxaban (in the dose approved for SPAF of 1 × 60mg/day or with dose reduction to 1 × 30mg/day, if creatinine clearance ≤ 50 ml/min, body weight ≤ 60 kg, or concomitant therapy with certain P-glycoprotein inhibitors [57]) in combination with a P2Y12 inhibitor in 1506 patients.